Deployment

Fitbit, founded in 2007 by James Park and Eric Friedman and acquired by Google in a roughly $2.1 billion deal that closed in January 2021, is now a Google product line rather than an independent company, and its devices are biometric-primary fitness bands and watches with atrial-fibrillation AI augmentation. Its current and last-generation devices include the Charge 6 from 2023, the Sense 2, and the Versa 4, carrying optical heart-rate sensing, ECG electrodes on the Sense line, a continuous electrodermal stress sensor on the Sense 2, blood oxygen, and skin temperature, plus Sleep Score, Sleep Profile, a Daily Readiness Score, and stress management. Its FDA clearances are the ECG app, cleared in September 2020 for on-demand assessment of atrial fibrillation versus sinus rhythm, and passive PPG-based Irregular Heart Rhythm Notifications, cleared on April 11, 2022 across a broad device range. Its blood oxygen, electrodermal stress, Sleep Score, and Daily Readiness features are wellness-grade and not FDA-cleared for any diagnostic claim. On current state, while standalone Fitbit-branded smartwatch hardware has been deprioritized with no Sense 3 and the smartwatch strategy consolidated onto the Pixel Watch, Google confirmed in October 2025 that new Fitbit hardware, expected to be trackers, is coming in 2026 along with a Fitbit Coach AI feature, so the line is deprioritized rather than dead. Its clinical-validation posture is the strongest in the cohort specifically on atrial fibrillation, anchored by the large prospective Fitbit Heart Study, while the 2026 Fitbit hardware specifications and the Fitbit Coach AI capabilities are unannounced and not verified.

Fitbit (Charge / Sense / Versa) by Fitbit · Operated by Fitbit · Catalog entry · 2 sources · not yet field-verified · Biometric wearables